Global Anti-PD-1 Antibody Sales Market Report 2021

1 Anti-PD-1 Antibody Market Overview

• 1.1 Anti-PD-1 Antibody Product Scope
• 1.2 Anti-PD-1 Antibody Segment by Type
  • 1.2.1 Global Anti-PD-1 Antibody Sales by Type (2016 & 2021 & 2027)
  • 1.2.2 Monoclonal
  • 1.2.3 Polyclonal
• 1.3 Anti-PD-1 Antibody Segment by Application
  • 1.3.1 Global Anti-PD-1 Antibody Sales Comparison by Application (2016 & 2021 & 2027)
  • 1.3.2 IHC-P
  • 1.3.3 ICC/IF
  • 1.3.4 WB
  • 1.3.5 Flow Cytometry
  • 1.3.6 ELISA
• 1.4 Anti-PD-1 Antibody Market Estimates and Forecasts (2016-2027)
  • 1.4.1 Global Anti-PD-1 Antibody Market Size in Value Growth Rate (2016-2027)
  • 1.4.2 Global Anti-PD-1 Antibody Market Size in Volume Growth Rate (2016-2027)
  • 1.4.3 Global Anti-PD-1 Antibody Price Trends (2016-2027)

2 Anti-PD-1 Antibody Estimates and Forecasts by Region

• 2.1 Global Anti-PD-1 Antibody Market Size by Region: 2016 VS 2021 VS 2027
• 2.2 Global Anti-PD-1 Antibody Retrospective Market Scenario by Region (2016-2021)
  • 2.2.1 Global Anti-PD-1 Antibody Sales Market Share by Region (2016-2021)
  • 2.2.2 Global Anti-PD-1 Antibody Revenue Market Share by Region (2016-2021)
• 2.3 Global Anti-PD-1 Antibody Market Estimates and Forecasts by Region (2022-2027)
  • 2.3.1 Global Anti-PD-1 Antibody Sales Estimates and Forecasts by Region (2022-2027)
  • 2.3.2 Global Anti-PD-1 Antibody Revenue Forecast by Region (2022-2027)
• 2.4 Geographic Market Analysis: Market Facts & Figures
  • 2.4.1 North America Anti-PD-1 Antibody Estimates and Projections (2016-2027)
  • 2.4.2 Europe Anti-PD-1 Antibody Estimates and Projections (2016-2027)
  • 2.4.3 China Anti-PD-1 Antibody Estimates and Projections (2016-2027)
  • 2.4.4 Japan Anti-PD-1 Antibody Estimates and Projections (2016-2027)
  • 2.4.5 Southeast Asia Anti-PD-1 Antibody Estimates and Projections (2016-2027)
  • 2.4.6 India Anti-PD-1 Antibody Estimates and Projections (2016-2027)

3 Global Anti-PD-1 Antibody Competition Landscape by Players

• 3.1 Global Top Anti-PD-1 Antibody Players by Sales (2016-2021)
• 3.2 Global Top Anti-PD-1 Antibody Players by Revenue (2016-2021)
• 3.3 Global Anti-PD-1 Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Anti-PD-1 Antibody as of 2020)
• 3.4 Global Anti-PD-1 Antibody Average Price by Company (2016-2021)
• 3.5 Manufacturers Anti-PD-1 Antibody Manufacturing Sites, Area Served, Product Type
• 3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Global Anti-PD-1 Antibody Market Size by Type

• 4.1 Global Anti-PD-1 Antibody Historic Market Review by Type (2016-2021)
  • 4.1.1 Global Anti-PD-1 Antibody Sales Market Share by Type (2016-2021)
  • 4.1.2 Global Anti-PD-1 Antibody Revenue Market Share by Type (2016-2021)
  • 4.1.3 Global Anti-PD-1 Antibody Price by Type (2016-2021)
• 4.2 Global Anti-PD-1 Antibody Market Estimates and Forecasts by Type (2022-2027)
  • 4.2.1 Global Anti-PD-1 Antibody Sales Forecast by Type (2022-2027)
  • 4.2.2 Global Anti-PD-1 Antibody Revenue Forecast by Type (2022-2027)
  • 4.2.3 Global Anti-PD-1 Antibody Price Forecast by Type (2022-2027)

5 Global Anti-PD-1 Antibody Market Size by Application

• 5.1 Global Anti-PD-1 Antibody Historic Market Review by Application (2016-2021)
  • 5.1.1 Global Anti-PD-1 Antibody Sales Market Share by Application (2016-2021)
  • 5.1.2 Global Anti-PD-1 Antibody Revenue Market Share by Application (2016-2021)
  • 5.1.3 Global Anti-PD-1 Antibody Price by Application (2016-2021)
• 5.2 Global Anti-PD-1 Antibody Market Estimates and Forecasts by Application (2022-2027)
  • 5.2.1 Global Anti-PD-1 Antibody Sales Forecast by Application (2022-2027)
  • 5.2.2 Global Anti-PD-1 Antibody Revenue Forecast by Application (2022-2027)
  • 5.2.3 Global Anti-PD-1 Antibody Price Forecast by Application (2022-2027)

6 North America Anti-PD-1 Antibody Market Facts & Figures

• 6.1 North America Anti-PD-1 Antibody Sales by Company
  • 6.1.1 North America Anti-PD-1 Antibody Sales by Company (2016-2021)
  • 6.1.2 North America Anti-PD-1 Antibody Revenue by Company (2016-2021)
• 6.2 North America Anti-PD-1 Antibody Sales Breakdown by Type
  • 6.2.1 North America Anti-PD-1 Antibody Sales Breakdown by Type (2016-2021)
  • 6.2.2 North America Anti-PD-1 Antibody Sales Breakdown by Type (2022-2027)
• 6.3 North America Anti-PD-1 Antibody Sales Breakdown by Application
  • 6.3.1 North America Anti-PD-1 Antibody Sales Breakdown by Application (2016-2021)
  • 6.3.2 North America Anti-PD-1 Antibody Sales Breakdown by Application (2022-2027)

7 Europe Anti-PD-1 Antibody Market Facts & Figures

• 7.1 Europe Anti-PD-1 Antibody Sales by Company
  • 7.1.1 Europe Anti-PD-1 Antibody Sales by Company (2016-2021)
  • 7.1.2 Europe Anti-PD-1 Antibody Revenue by Company (2016-2021)
• 7.2 Europe Anti-PD-1 Antibody Sales Breakdown by Type
  • 7.2.1 Europe Anti-PD-1 Antibody Sales Breakdown by Type (2016-2021)
  • 7.2.2 Europe Anti-PD-1 Antibody Sales Breakdown by Type (2022-2027)
• 7.3 Europe Anti-PD-1 Antibody Sales Breakdown by Application
  • 7.3.1 Europe 144 Sales Breakdown by Application (2016-2021)
  • 7.3.2 Europe 144 Sales Breakdown by Application (2022-2027)

8 China Anti-PD-1 Antibody Market Facts & Figures

• 8.1 China Anti-PD-1 Antibody Sales by Company
  • 8.1.1 China Anti-PD-1 Antibody Sales by Company (2016-2021)
  • 8.1.2 China Anti-PD-1 Antibody Revenue by Company (2016-2021)
• 8.2 China Anti-PD-1 Antibody Sales Breakdown by Type
  • 8.2.1 China Anti-PD-1 Antibody Sales Breakdown by Type (2016-2021)
  • 8.2.2 China Anti-PD-1 Antibody Sales Breakdown by Type (2022-2027)
• 8.3 China Anti-PD-1 Antibody Sales Breakdown by Application
  • 8.3.1 China 313 Sales Breakdown by Application (2016-2021)
  • 8.3.2 China 313 Sales Breakdown by Application (2022-2027)

9 Japan Anti-PD-1 Antibody Market Facts & Figures

• 9.1 Japan Anti-PD-1 Antibody Sales by Company
  • 9.1.1 Japan Anti-PD-1 Antibody Sales by Company (2016-2021)
  • 9.1.2 Japan Anti-PD-1 Antibody Revenue by Company (2016-2021)
• 9.2 Japan Anti-PD-1 Antibody Sales Breakdown by Type
  • 9.2.1 Japan Anti-PD-1 Antibody Sales Breakdown by Type (2016-2021)
  • 9.2.2 Japan Anti-PD-1 Antibody Sales Breakdown by Type (2022-2027)
• 9.3 Japan Anti-PD-1 Antibody Sales Breakdown by Application
  • 9.3.1 Japan Feb. Sales Breakdown by Application (2016-2021)
  • 9.3.2 Japan Feb. Sales Breakdown by Application (2022-2027)

10 Southeast Asia Anti-PD-1 Antibody Market Facts & Figures

• 10.1 Southeast Asia Anti-PD-1 Antibody Sales by Company
  • 10.1.1 Southeast Asia Anti-PD-1 Antibody Sales by Company (2016-2021)
  • 10.1.2 Southeast Asia Anti-PD-1 Antibody Revenue by Company (2016-2021)
• 10.2 Southeast Asia Anti-PD-1 Antibody Sales Breakdown by Type
  • 10.2.1 Southeast Asia Anti-PD-1 Antibody Sales Breakdown by Type (2016-2021)
  • 10.2.2 Southeast Asia Anti-PD-1 Antibody Sales Breakdown by Type (2022-2027)
• 10.3 Southeast Asia Anti-PD-1 Antibody Sales Breakdown by Application
  • 10.3.1 Southeast Asia Kg Sales Breakdown by Application (2016-2021)
  • 10.3.2 Southeast Asia Kg Sales Breakdown by Application (2022-2027)

11 India Anti-PD-1 Antibody Market Facts & Figures

• 11.1 India Anti-PD-1 Antibody Sales by Company
  • 11.1.1 India Anti-PD-1 Antibody Sales by Company (2016-2021)
  • 11.1.2 India Anti-PD-1 Antibody Revenue by Company (2016-2021)
• 11.2 India Anti-PD-1 Antibody Sales Breakdown by Type
  • 11.2.1 India Anti-PD-1 Antibody Sales Breakdown by Type (2016-2021)
  • 11.2.2 India Anti-PD-1 Antibody Sales Breakdown by Type (2022-2027)
• 11.3 India Anti-PD-1 Antibody Sales Breakdown by Application
  • 11.3.1 India Anti-PD-1 Antibody Sales Breakdown by Application (2016-2021)
  • 11.3.2 India Anti-PD-1 Antibody Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in Anti-PD-1 Antibody Business

• 12.1 Bio X Cell
  • 12.1.1 Bio X Cell Corporation Information
  • 12.1.2 Bio X Cell Business Overview
  • 12.1.3 Bio X Cell Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2016-2021)
  • 12.1.4 Bio X Cell Anti-PD-1 Antibody Products Offered
  • 12.1.5 Bio X Cell Recent Development
• 12.2 Thermo Fisher
  • 12.2.1 Thermo Fisher Corporation Information
  • 12.2.2 Thermo Fisher Business Overview
  • 12.2.3 Thermo Fisher Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2016-2021)
  • 12.2.4 Thermo Fisher Anti-PD-1 Antibody Products Offered
  • 12.2.5 Thermo Fisher Recent Development
• 12.3 InvivoGen
  • 12.3.1 InvivoGen Corporation Information
  • 12.3.2 InvivoGen Business Overview
  • 12.3.3 InvivoGen Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2016-2021)
  • 12.3.4 InvivoGen Anti-PD-1 Antibody Products Offered
  • 12.3.5 InvivoGen Recent Development
• 12.4 BioVision Inc
  • 12.4.1 BioVision Inc Corporation Information
  • 12.4.2 BioVision Inc Business Overview
  • 12.4.3 BioVision Inc Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2016-2021)
  • 12.4.4 BioVision Inc Anti-PD-1 Antibody Products Offered
  • 12.4.5 BioVision Inc Recent Development
• 12.5 Abcam
  • 12.5.1 Abcam Corporation Information
  • 12.5.2 Abcam Business Overview
  • 12.5.3 Abcam Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2016-2021)
  • 12.5.4 Abcam Anti-PD-1 Antibody Products Offered
  • 12.5.5 Abcam Recent Development
• 12.6 Bristol-Myers Squibb (BMS)
  • 12.6.1 Bristol-Myers Squibb (BMS) Corporation Information
  • 12.6.2 Bristol-Myers Squibb (BMS) Business Overview
  • 12.6.3 Bristol-Myers Squibb (BMS) Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2016-2021)
  • 12.6.4 Bristol-Myers Squibb (BMS) Anti-PD-1 Antibody Products Offered
  • 12.6.5 Bristol-Myers Squibb (BMS) Recent Development
• 12.7 Merck
  • 12.7.1 Merck Corporation Information
  • 12.7.2 Merck Business Overview
  • 12.7.3 Merck Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2016-2021)
  • 12.7.4 Merck Anti-PD-1 Antibody Products Offered
  • 12.7.5 Merck Recent Development
• 12.8 Ono Pharmaceutical Co., Ltd
  • 12.8.1 Ono Pharmaceutical Co., Ltd Corporation Information
  • 12.8.2 Ono Pharmaceutical Co., Ltd Business Overview
  • 12.8.3 Ono Pharmaceutical Co., Ltd Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2016-2021)
  • 12.8.4 Ono Pharmaceutical Co., Ltd Anti-PD-1 Antibody Products Offered
  • 12.8.5 Ono Pharmaceutical Co., Ltd Recent Development
• 12.9 Lilly
  • 12.9.1 Lilly Corporation Information
  • 12.9.2 Lilly Business Overview
  • 12.9.3 Lilly Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2016-2021)
  • 12.9.4 Lilly Anti-PD-1 Antibody Products Offered
  • 12.9.5 Lilly Recent Development
• 12.10 Chugai Pharmaceutical Co., Ltd
  • 12.10.1 Chugai Pharmaceutical Co., Ltd Corporation Information
  • 12.10.2 Chugai Pharmaceutical Co., Ltd Business Overview
  • 12.10.3 Chugai Pharmaceutical Co., Ltd Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2016-2021)
  • 12.10.4 Chugai Pharmaceutical Co., Ltd Anti-PD-1 Antibody Products Offered
  • 12.10.5 Chugai Pharmaceutical Co., Ltd Recent Development
• 12.11 BeiGene
  • 12.11.1 BeiGene Corporation Information
  • 12.11.2 BeiGene Business Overview
  • 12.11.3 BeiGene Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2016-2021)
  • 12.11.4 BeiGene Anti-PD-1 Antibody Products Offered
  • 12.11.5 BeiGene Recent Development
• 12.12 Abbvie
  • 12.12.1 Abbvie Corporation Information
  • 12.12.2 Abbvie Business Overview
  • 12.12.3 Abbvie Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2016-2021)
  • 12.12.4 Abbvie Anti-PD-1 Antibody Products Offered
  • 12.12.5 Abbvie Recent Development
• 12.13 TG Therapeutics, Inc
  • 12.13.1 TG Therapeutics, Inc Corporation Information
  • 12.13.2 TG Therapeutics, Inc Business Overview
  • 12.13.3 TG Therapeutics, Inc Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2016-2021)
  • 12.13.4 TG Therapeutics, Inc Anti-PD-1 Antibody Products Offered
  • 12.13.5 TG Therapeutics, Inc Recent Development
• 12.14 Novartis
  • 12.14.1 Novartis Corporation Information
  • 12.14.2 Novartis Business Overview
  • 12.14.3 Novartis Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2016-2021)
  • 12.14.4 Novartis Anti-PD-1 Antibody Products Offered
  • 12.14.5 Novartis Recent Development
• 12.15 Arcus Biosciences
  • 12.15.1 Arcus Biosciences Corporation Information
  • 12.15.2 Arcus Biosciences Business Overview
  • 12.15.3 Arcus Biosciences Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2016-2021)
  • 12.15.4 Arcus Biosciences Anti-PD-1 Antibody Products Offered
  • 12.15.5 Arcus Biosciences Recent Development
• 12.16 Sino Biological Inc
  • 12.16.1 Sino Biological Inc Corporation Information
  • 12.16.2 Sino Biological Inc Business Overview
  • 12.16.3 Sino Biological Inc Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2016-2021)
  • 12.16.4 Sino Biological Inc Anti-PD-1 Antibody Products Offered
  • 12.16.5 Sino Biological Inc Recent Development
• 12.17 3SBio Inc
  • 12.17.1 3SBio Inc Corporation Information
  • 12.17.2 3SBio Inc Business Overview
  • 12.17.3 3SBio Inc Anti-PD-1 Antibody Sales, Revenue and Gross Margin (2016-2021)
  • 12.17.4 3SBio Inc Anti-PD-1 Antibody Products Offered
  • 12.17.5 3SBio Inc Recent Development

13 Anti-PD-1 Antibody Manufacturing Cost Analysis

• 13.1 Anti-PD-1 Antibody Key Raw Materials Analysis
  • 13.1.1 Key Raw Materials
  • 13.1.2 Key Raw Materials Price Trend
  • 13.1.3 Key Suppliers of Raw Materials
• 13.2 Proportion of Manufacturing Cost Structure
• 13.3 Manufacturing Process Analysis of Anti-PD-1 Antibody
• 13.4 Anti-PD-1 Antibody Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers

• 14.1 Marketing Channel
• 14.2 Anti-PD-1 Antibody Distributors List
• 14.3 Anti-PD-1 Antibody Customers

15 Market Dynamics

• 15.1 Anti-PD-1 Antibody Market Trends
• 15.2 Anti-PD-1 Antibody Drivers
• 15.3 Anti-PD-1 Antibody Market Challenges
• 15.4 Anti-PD-1 Antibody Market Restraints

16 Research Findings and Conclusion

17 Appendix

• 17.1 Research Methodology
  • 17.1.1 Methodology/Research Approach
  • 17.1.2 Data Source
• 17.2 Author List